Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder

NCT06793397 is registered in ClinicalTrials.gov with Cybin IRL Limited as lead sponsor.

NCT NCT06793397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Lead sponsor
Cybin IRL Limited
Phase
Phase 3
Overall status
Recruiting
Start date
December 10, 2025
Completion date
August 9, 2027
Enrollment
330 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

depression, depression - major depressive disorder, depression disorder, depression disorders, depression in adults, major depressive disorder (mdd)